Status:
NOT_YET_RECRUITING
Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma .
Lead Sponsor:
Assiut University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
20-85 years
Brief Summary
Role of ADC value and DWI in abbreviated MRI compared to post-contrast CT in follow-up of HCC after TACE.
Detailed Description
Hepatocellular carcinoma (HCC) is the 5th most common cancer in the world and the most common in Egypt . Trans-arterial chemoembolization (TACE) is the treatment recommended for unresectable HCC acco...
Eligibility Criteria
Inclusion
- Patients who underwent TACE for unresectable HCC with patent portal vein based on Doppler, no ascites, and satisfactory liver function.
- Age between 20-year old and 85-year old
Exclusion
- Estimated GFR less than 60 Previous history of severe allergic reaction to the iodinated contrast agent Patients with claustrophobia who can't undergo MR examination. Patients having cochlear implants or cardiac pacemaker
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2027
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT06168357
Start Date
January 1 2024
End Date
September 30 2027
Last Update
December 13 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.